Quick Search:

uzh logo
Browse by:

Zurich Open Repository and Archive

Maintenance: Tuesday, July the 26th 2016, 07:00-10:00

ZORA's new graphical user interface will be relaunched (For further infos watch out slideshow ZORA: Neues Look & Feel). There will be short interrupts on ZORA Service between 07:00am and 10:00 am. Please be patient.

Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-59067

Leo, C; Fink, D (2011). Erythropoietin in der onkologischen Therapie – was wissen wir über die Risiken? Praxis, 100(20):1239-46.

[img]Published Version
PDF - Registered users only
View at publisher


Erythropoietin is a glycoprotein predominantly produced in the kidney. It is an essential regulator of erythropoiesis in the bone marrow. Although cancer-associated anemia is caused by multiple factors, recombinant erythropoietin (rhuEpo) was widely used to treat and prevent this condition. Several clinical studies showed that the use of rhuEpo results in an efficient reduction of red blood cell transfusions in cancer-associated anemia. However, over the past twenty years, Epo and its receptor EpoR were found to be expressed also outside the hematopoietic system and in malignant tumors. This led to a discussion concerning potential risks associated with the application of erythropoiesis-stimulating agents in oncology.




2 downloads since deposited on 17 Feb 2012
0 downloads since 12 months

Detailed statistics

Additional indexing

Other titles:Erythropoietinin oncologic therapy - what so we know about the risks?
Item Type:Journal Article, refereed, further contribution
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Gynecology
Dewey Decimal Classification:610 Medicine & health
Deposited On:17 Feb 2012 12:24
Last Modified:05 Apr 2016 15:36
Publisher:Hans Huber
ISSN:1661-8157 (P) 1661-8165 (E)
Publisher DOI:10.1024/1661-8157/a000689
PubMed ID:21971618

Users (please log in): suggest update or correction for this item

Repository Staff Only: item control page